Web: | mayocliniclabs.com |
---|---|
Email: | mcl@mayo.edu |
Telephone: | 800-533-1710 |
International: | +1 855-379-3115 |
Values are valid only on day of printing. |
Determination of EGFR T790M mutation status in blood specimens as an alternative to invasive tissue biopsies
Identification of patients with non-small cell lung cancer who harbor a T790M mutation and may benefit from specific EGFR-targeted therapies
This test evaluates cell-free DNA (cfDNA) in the peripheral blood for the presence of the EGFR T790M mutation in patients with non-small cell lung cancer (NSCLC) and can be used to assess eligibility for targeted therapies. Current data suggests that patients with metastatic NSCLC and the T790M mutation may benefit from T790M-targeted therapy (eg, osimertinib).
This test is not validated for serial monitoring of patients with cancer. This test is also not intended as a screening test to identify cancer.
Evaluates peripheral blood for the presence of the T790M mutation in the EGFR gene in cell-free DNA
Rapid detection of the EGFR T790M mutation in non-small cell lung cancer patients as an alternative for EGFR analysis of tissue
Current data suggests that patients with metastatic NSCLC and the T790M mutation may benefit from T790M-targeted therapy (eg, osimertinib)
Digital Droplet Polymerase Chain Reaction (PCR) of Plasma Cell-Free DNA